聚乙二醇干扰素联合利巴韦林治疗老年慢性丙型肝炎的疗效和安全性评价

摘要

目的 分析聚乙二醇干扰素(PEG-IFN-2α)联合利巴韦林治疗老年慢性丙型肝炎(CHC)的疗效和安全性. 方法 老年CHC患者(≥60岁,老年组)与中青年CHC患者(＜60岁,非老年组)各20例接受PEG-IFN-2α 180 μg每周1次,利巴韦林15 mg/(kg·d)联合治疗.比较2组患者在病毒应答和不良反应发生率等方面的差异. 结果 与非老年组比较,老年组快速病毒学应答(RVR)及治疗结束时病毒学应答(ETR)无明显差异(P＞0.05),持续病毒学应答(SVR)率显著降低(P＜0.05).老年组血红蛋白降低,中性粒细胞绝对值减少,皮疹、脱发、皮肤瘙瘁等不良反应的发生率显著升高(P＜0.05). 结论 PEG-IFN-2α联合利巴韦林治疗老年CHC是安全有效的.%Objective To evaluate the efficacy and security of the combination therapy of pegylated interferon-2α (PEG-IFN-2α) with ribavirin for chronic hepatitis C(CHC) in the elderly patients.Methods Twenty elderly patients with CHC (≥60 years old) and 20 non-elderly patients(＜ 60 years old) accepted combination therapy of PEG-IFN-2α with ribavirin[15mg/(kg·d)].Virological response and the incidence rate of adverse effect were compared between the two groups.Results Compared with the group of younger patients,The level of rapid virological response (RVR) and end of treatment response(ETR) (P ＞ 0.05)showed no significant difference and the level of sustained virological response (SVR) was significantly decreased in the elderly patients(P ＜ 0.05).In the elderly patients,the level of hemoglobin was decreased and the absolute neutropenia count was reduced,and the incidence rate of erythra,alopecia and itch of skin was significantly increased,compared with no-elderly patients(P ＜ 0.05).Conclusions Combination therapy of PEG-IFN-2α with ribavirin is comparably effective and safe in the elderly patients with CHC.